Loading...
Market
Story
Merck's HPV Vaccine for Men Approved by China’s Drug Regulator for Ages 9-26, First of Its Kind
Jan 8, 2025, 04:50 AM
China's drug regulator has approved Merck's human papillomavirus (HPV) vaccine for men, marking a significant expansion for the U.S. pharmaceutical company in an emerging market. The vaccine is specifically authorized for males aged 9 to 26 and is the first of its kind in China. This approval comes after a decline in demand among women for the vaccine, which had previously surged. Merck's announcement, made via its Chinese subsidiary, MSD, highlights the potential for growth in a new demographic following the approval by China's medical products administration.
View original story
Similar markets
Children • 25%
Immunocompromised • 25%
General population • 25%
Elderly • 25%
Elderly over 65 • 25%
Children under 5 • 25%
Ages 5-18 • 25%
Ages 19-64 • 25%
65 and older • 25%
5-18 years • 25%
Children under 5 • 25%
19-64 years • 25%
No • 50%
Yes • 50%
Public health campaigns • 25%
Travel restrictions • 25%
No major action • 25%
Increased healthcare funding • 25%
Other • 25%
Face masks • 25%
Hand washing • 25%
Social distancing • 25%